# Actinium Pharmaceuticals, Inc.: overview ATNM · NYSE · CIK 1388320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/atnm.md) · [Financials](/companies/atnm/financials.md) · [Filings](/companies/atnm/filings.md) · [Insiders](/companies/atnm/insiders.md) Latest reported revenue: [$35.0m](/filings/0001213900-26-086769.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-086769). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | [0.1](/filings/0001213900-25-110979.md) | [0.0 d](/filings/0001213900-26-036504.md) | not reported | [35.0](/filings/0001213900-26-086769.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | [(6324.4%)](/filings/0001213900-25-110979.md) | not reported | not reported | [78.8%](/filings/0001213900-26-086769.md) | | Net margin | % | not reported | not reported | not reported | not reported | [(5701.1%)](/filings/0001213900-25-110979.md) | not reported | not reported | [79.7%](/filings/0001213900-26-086769.md) | | Diluted EPS | $ per share | [(0.37)](/filings/0001213900-25-110979.md) | not reported | [(0.51)](/filings/0001213900-26-053980.md) | [(0.22)](/filings/0001213900-26-086769.md) | [(0.16)](/filings/0001213900-25-110979.md) | not reported | [(0.18)](/filings/0001213900-26-053980.md) | [0.89](/filings/0001213900-26-086769.md) | | Free cash flow | $m | [(12.0) d](/filings/0001213900-25-110979.md) | [(5.8) d](/filings/0001213900-26-036504.md) | not reported | not reported | not reported | not reported | [(5.9)](/filings/0001213900-26-053980.md) | [(5.7) d](/filings/0001213900-26-086769.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.1](/filings/0001213900-23-025597.md) | [1.0](/filings/0001213900-24-028038.md) | [0.1](/filings/0001213900-25-026371.md) | not reported | [0.1](/filings/0001213900-26-036504.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(2182.2%)](/filings/0001213900-23-025597.md) | [(3311.1%)](/filings/0001213900-24-028038.md) | [(64098.8%)](/filings/0001213900-25-026371.md) | not reported | [(40274.4%)](/filings/0001213900-26-036504.md) | | Net margin | % | [(2165.6%)](/filings/0001213900-23-025597.md) | [(3205.5%)](/filings/0001213900-24-028038.md) | [(60269.1%)](/filings/0001213900-25-026371.md) | not reported | [(37652.2%)](/filings/0001213900-26-036504.md) | | Diluted EPS | $ per share | [(1.20)](/filings/0001213900-23-025597.md) | [(1.37)](/filings/0001213900-24-028038.md) | [(1.83)](/filings/0001213900-25-026371.md) | [(1.27)](/filings/0001213900-26-036504.md) | [(1.09)](/filings/0001213900-26-036504.md) | | Free cash flow | $m | [(21.0)](/filings/0001213900-23-025597.md) | [8.3](/filings/0001213900-24-028038.md) | [(47.5)](/filings/0001213900-25-026371.md) | [(33.1)](/filings/0001213900-26-036504.md) | [(24.7)](/filings/0001213900-26-036504.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/atnm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.2m | 1,238,302 | | Reduced −17,214 | | [COMPASS FINANCIAL MANAGEMENT LLC](/funds/2148724.md) | 2026-06-30 | $588.2k | 600,230 | | Not compared | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $504.3k | 514,580 | | Reduced −50,020 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $388.0k | 395,896 | | Added +24,686 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $372.9k | 380,491 | | Reduced −91,109 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $318.6k | 324,945 | | Reduced −11,128 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $254.0k | 259,179 | | Reduced −77,989 | | [GAGNON SECURITIES LLC](/funds/1125725.md) | 2026-06-30 | $178.5k | 182,142 | | Reduced −19,158 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $158.3k | 161,526 | | Added +1,261 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $119.8k | 122,215 | | Reduced −4,000 | ## Recent filings [All 496 filings](/companies/atnm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 11:42 ET | [DEF 14A](/filings/0001213900-26-110022.md) | Proxy statement, period 2026-11-25 | 0001213900-26-110022 | | 2026-10-15 | 21:05 ET | [8-K](/filings/0001213900-26-109884.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-109884 | | 2026-08-14 | 21:00 ET | [8-K](/filings/0001213900-26-090232.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-090232 | | 2026-08-07 | 21:00 ET | [10-Q](/filings/0001213900-26-086769.md) | Quarterly report, period 2026-06-30 | 0001213900-26-086769 | | 2026-06-18 | 21:00 ET | [8-K](/filings/0001213900-26-070193.md) | 8.01 Other events | 0001213900-26-070193 | | 2026-05-29 | 21:10 ET | [8-K](/filings/0001213900-26-062935.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-062935 | | 2026-05-08 | 21:00 ET | [10-Q](/filings/0001213900-26-053980.md) | Quarterly report, period 2026-03-31 | 0001213900-26-053980 | | 2026-03-30 | 21:39 ET | [10-K](/filings/0001213900-26-036504.md) | Annual report, period 2025-12-31 | 0001213900-26-036504 | | 2026-03-26 | 21:00 ET | [8-K/A](/filings/0001213900-26-034807.md) | 5.07 Shareholder vote results | 0001213900-26-034807 | | 2026-02-13 | 22:00 ET | [8-K](/filings/0001213900-26-016559.md) | 5.02 Departure or appointment of officers or directors | 0001213900-26-016559 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-036504.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7fe1911f-0c36-4746-877e-1f58b0374c10) ## About the filer - CIK: 1388320 - Tickers: ATNM - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.